![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Comedications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy Washington D.C., May 26-28, 2015
A.R. Polepally1, P. S. Badri1, A. Parikh1, L. Rodrigues-Jr2, B. A. Da Silva-Tillmann3, S. Mensing1, T. J. Podsadecki2, W. M. Awni1, S. Dutta1, R. M. Menon1 1AbbVie Inc., Clinical Pharmacology and Pharmacometrics, North Chicago, IL, 60064; 2AbbVie Inc., Infectious Disease Development, North Chicago, IL, 60064; 3AbbVie Inc., Global Pharmacovigilence, North Chicago, IL, 60064
Clinical Pharm of HIV & Hepatitis Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir: Drug Interactions with Antiretroviral Agents - (06/01/15)
Clinical Pharm of HIV & Hepatitis Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/03/15)
![Pharm1.gif](../images/060915/060815-11/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-11/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-11/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-11/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-11/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-11/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-11/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-11/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-11/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-11/Pharm10.gif)
![Pharm11.gif](../images/060915/060815-11/Pharm11.gif)
![Pharm12.gif](../images/060915/060815-11/Pharm12.gif)
![Pharm13.gif](../images/060915/060815-11/Pharm13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|